Granite Investment Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Granite Investment Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$397K	Sell	1,646 -111	-6%	-$24.3K	0.02%	204
2026 Q1	$332K	Buy	1,757 +212	+14%	+$37K	0.02%	208
2025 Q4	$263K	Sell	1,545 -7,630	-83%	-$1.17M	0.02%	218
2025 Q3	$1.21M	Sell	9,175 -9,309	-50%	-$1.12M	0.07%	188
2025 Q2	$1.96M	Sell	18,484 -3,037	-14%	-$330K	0.1%	177
2025 Q1	$2.67M	Buy	+21,521	New	+$2.81M	0.14%	168
2023 Q2	–	Sell	-36,983	Closed	-$5.41M	–	267
2023 Q1	$5.41M	Buy	+36,983	New	+$5.47M	0.23%	132

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Granite Investment Partners's JAZZ Position: Q2 2026 in Review

Granite Investment Partners reduced its Jazz Pharmaceuticals (JAZZ) stake by 6.3% in Q2 2026, selling an estimated $24.3K and leaving 1,646 shares worth $397K. The position accounts for 0.02% of the portfolio, ranked #204.

Granite Investment Partners first reported a position in JAZZ in Q1 2023 and has held it in 7 quarters since. The position peaked at $5.41M in Q1 2023. 647 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Granite Investment Partners held 1,646 shares of Jazz Pharmaceuticals worth $397K as of Q2 2026.
Granite Investment Partners sold 111 Jazz Pharmaceuticals shares in Q2 2026, an estimated $24.3K.
Jazz Pharmaceuticals made up 0.02% of Granite Investment Partners's portfolio in Q2 2026, its #204 holding.
Granite Investment Partners first reported a position in Jazz Pharmaceuticals in Q1 2023 and has held it in 7 quarters since.
Granite Investment Partners's Jazz Pharmaceuticals position peaked at $5.41M in Q1 2023.
647 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Granite Investment Partners's 13F filing for Q2 2026, filed 7 Aug 2026.